Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96LA9
UPID:
MRGX4_HUMAN
Alternative names:
Sensory neuron-specific G-protein coupled receptor 5/6
Alternative UPACC:
Q96LA9; Q3KNU3; Q3KNU4; Q502W0; Q8TDD6; Q8TDD7
Background:
Mas-related G-protein coupled receptor member X4 (MrgX4) is identified as an orphan receptor, primarily implicated in the modulation and sensation of pain. It is believed to play a crucial role in nociceptive neurons, influencing pain perception through its potent activation by enkephalins, substances known for their pain-relieving properties.
Therapeutic significance:
Understanding the role of Mas-related G-protein coupled receptor member X4 could open doors to potential therapeutic strategies, especially in the management and treatment of pain, offering a promising avenue for novel analgesic drug development.